Pfäfflin, F.; Theloe, A.; Stegemann, M.S.; Leistner, R.; Sander, L.E.; Kurth, F.; Achterberg, S.
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study. Antibiotics 2025, 14, 773.
https://doi.org/10.3390/antibiotics14080773
AMA Style
Pfäfflin F, Theloe A, Stegemann MS, Leistner R, Sander LE, Kurth F, Achterberg S.
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study. Antibiotics. 2025; 14(8):773.
https://doi.org/10.3390/antibiotics14080773
Chicago/Turabian Style
Pfäfflin, Frieder, Anja Theloe, Miriam Songa Stegemann, Rasmus Leistner, Leif Erik Sander, Florian Kurth, and Stephan Achterberg.
2025. "Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study" Antibiotics 14, no. 8: 773.
https://doi.org/10.3390/antibiotics14080773
APA Style
Pfäfflin, F., Theloe, A., Stegemann, M. S., Leistner, R., Sander, L. E., Kurth, F., & Achterberg, S.
(2025). Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study. Antibiotics, 14(8), 773.
https://doi.org/10.3390/antibiotics14080773
